Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)

American Heart Journal

Volumn 151, Issue 3, 2006, Pages 713-719

  Gage, Brian F ^a   Yan, Yan ^a   Milligan, Paul E ^a   Waterman, Amy D ^a   Culverhouse, Robert ^a   Rich, Michael W ^a   Radford, Martha J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTICOAGULANT AGENT; WARFARIN;

ACCURACY; ADULT; AGED; ALCOHOL ABUSE; ANEMIA; ARTICLE; BLEEDING; DISEASE CLASSIFICATION; FALL RISK; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEREDITY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; MALE; REGISTRIES; RISK FACTORS;

EID: 33344461585     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.04.017     Document Type: Article

References (59)

1. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Arch Intern Med 154 1994 1449 1457
2. C. van Walraven, R.G. Hart, and D.E. Singer Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis JAMA 288 2002 2441 2448
3. S.B. Olsson for the Executive Steering Committee on behalf of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
4. M. Hurlen, M. Abdelnoor, and P. Smith Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
5. R.F. van Es, J.J. Jonker, and F.W. Verheugt Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial Lancet 360 2002 109 113
6. P.M. Ridker, S.Z. Goldhaber, and E. Danielson Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism N Engl J Med 348 2003 1425 1434
7. C.W. Francis, B.L. Davidson, and S.D. Berkowitz Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial Ann Intern Med 137 2002 648 655
8. C.S. Landefeld, and L. Goldman Major bleeding in outpatients with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 1989 144 152
9. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
10. P.M. Kuijer, B.A. Hutten, and M.H. Prins Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 159 1999 457 460
11. C. Kearon, J.S. Ginsberg, and M.J. Kovacs Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism N Engl J Med 349 2003 631 639
12. J.H. Gurwitz, T.S. Field, and L.R. Harrold Incidence and preventability of adverse drug events among older persons in the ambulatory setting JAMA 289 2003 1107 1116
13. J.H. Gurwitz, T.S. Field, and J. Judge The incidence of adverse drug events in two large academic long-term care facilities Am J Med 118 2005 251 258
14. B.F. Gage, M. Boechler, and A.L. Doggette Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation Stroke 31 2000 822 827
15. A.S. Go, E.M. Hylek, and L.H. Borowsky Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
16. R.J. Beyth, M.R. Antani, and K.E. Covinsky Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 11 1996 721 728
17. C.P. Gross, E.W. Vogel, and A.J. Dhond Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey Clin Ther 25 2003 1750 1764
18. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
19. T.J. Wang, J.M. Massaro, and D. Levy A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
20. R.G. Hart, L.A. Pearce, and R. McBride Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials Stroke 30 1999 1223 1229
21. C. van Walraven, R.G. Hart, and G.A. Wells A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin Arch Intern Med 163 2003 936 943
22. C.L. O'Brien, and B.F. Gage Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation JAMA 293 2005 699 706
23. R.J. Beyth, L. Quinn, and C.S. Landefeld A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial Ann Intern Med 133 2000 687 695
24. J. Monette, J.H. Gurwitz, and P.A. Rochon Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners J Am Geriatr Soc 45 1997 1060 1065
25. S.D. Weisbord, J. Whittle, and R.C. Brooks Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med 16 2001 743 749
26. C.S. Landefeld, E. McGuire III, and M.W. Rosenblatt A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy Am J Med 89 1990 569 578
27. C.S. Landefeld, E.F. Cook, and M. Flatley Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy Am J Med 82 1987 703 713
28. F.J.M. van der Meer, F.R. Rosendaal, and J.P. Vandenbroucke Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants Thromb Haemost 76 1996 12 16
29. D.A. McMahan, D.M. Smith, and M.A. Carey Risk of major hemorrhage for outpatients treated with warfarin J Gen Intern Med 13 1998 311 316
30. H.K. Nieuwenhuis, J. Albada, and J.D. Banga Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin Blood 78 1991 2337 2343
31. Stroke Prevention in Atrial Fibrillation Investigators Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 1996 409 416
32. J. Launbjerg, H. Egeblad, and J. Heaf Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients J Int Med 229 1991 351 355
33. G. Palareti, J. Hirsh, and C. Legnani Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study Arch Intern Med 160 2000 470 478
34. W.M. Feinberg, J.L. Blackshear, and A. Laupacis Prevalence, age distribution, and gender of patients with atrial fibrillation Arch Intern Med 155 1995 469 473
35. R.J. Beyth, P.E. Milligan, and B.F. Gage Risk factors for bleeding in patients taking coumarins Curr Hematol Rep 1 2002 41 49
36. T.I. Shireman, P.A. Howard, and T.F. Kresowik Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients Stroke 35 2004 2362 2367
37. M.K. Higashi, D.L. Veenstra, and L.M. Kondo Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
38. M. Margaglione, D. Colaizzo, and G. D'Andrea Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
39. L.E. Visser, R.H. van Schaik, and M. van Vliet The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon Thromb Haemost 92 2004 61 66
40. D. Voora, C. Eby, and M.W. Linder Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype Thromb Haemost 93 2005 700 705
41. J. Corral, J.A. Iniesta, and R. Gonzalez-Conejero Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage Blood 97 2001 2979 2982
42. B. Gage, E. Birman-Deych, and R. Kerzner Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall Am J Med 118 2005 612 617
43. S.F. Jencks, and G.R. Wilensky The Health Care Quality Improvement Initiative. A new approach to quality assurance in Medicare JAMA 268 1992 900 903
44. R.H. White, R.J. Beyth, and H. Zhou Major bleeding after hospitalization for deep-venous thrombosis Am J Med 107 1999 414 424
45. E. Birman-Deych, A.D. Waterman, and Y. Yan Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors Med Care 43 2005 480 485
46. H.C. Kraemer, V.S. Periyakoil, and A. Noda Kappa coefficients in medical research Stat Med 21 2002 2109 2129
47. F.E. Harrell Jr, K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
48. B. Efron, and R. Tibshirani An introduction to the bootstrap 1993 Chapman & Hall New York
49. E. Graf, C. Schmoor, and W. Sauerbrei Assessment and comparison of prognostic classification schemes for survival data Stat Med 18 1999 2529 2545
50. B.F. Gage, C. van Walraven, and L. Pearce Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation 110 2004 2287 2292
51. A.L. Gulløv, B.G. Koefoed, and P. Petersen Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation Arch Intern Med 159 1999 1222 1228
52. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
53. S.D. Fihn, M. McDonell, and D. Martin Risk factors for complications of chronic anticoagulation. A multicenter study Ann Intern Med 118 1993 511 520
54. P.S. Wells, M.A. Forgie, and M. Simms The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism Arch Intern Med 163 2003 917 920
55. L.D. Fiore, M.D. Ezekowitz, and M.T. Brophy Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study Circulation 105 2002 557 563
56. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
57. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
58. J.C. Cappelleri, L.D. Fiore, and M.T. Brophy Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis Am Heart J 130 1995 547 552
59. P. Laffort, R. Roudaut, and X. Roques Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study J Am Coll Cardiol 35 2000 739 746